Sigrid Therapeutics obtains US patent covering the use of a novel silica-based biomaterial SiPore15® for the treatment and prevention of obesity
Stockholm, Sweden July 1, 2020. Sigrid Therapeutics, a Swedish clinical-stage technology company specializing in the prevention of type-2 diabetes and obesity, today announced that the Company has been granted a US patent by the United States Patent and Trademark Office (USPTO). The patent covers the use of the Company’s breakthrough, mesoporous silica particles (MSP)-based device SiPore15® for lowering of body fat, prevention and treatment of obesity. The patent (US 10,695,294) provides exclusive rights to the exploitation of the Company’s lead product in the US until 2033. The US